Ignite Creation Date:
2025-12-25 @ 3:45 AM
Ignite Modification Date:
2026-03-03 @ 4:27 AM
Study NCT ID:
NCT02799602
Status:
COMPLETED
Last Update Posted:
2025-12-04
First Post:
2016-06-06
Is NOT Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
Darolutamide in Addition to Standard Androgen Deprivation Therapy and Docetaxel in Metastatic Hormone-Sensitive Prostate Cancer
Sponsor:
Bayer
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2016-11-30
Start Date Type:
ACTUAL
Primary Completion Date:
2021-10-25
Primary Completion Date Type:
ACTUAL
Completion Date:
2023-04-11
Completion Date Type:
ACTUAL
First Submit Date:
2016-06-06
First Submit QC Date:
None
Study First Post Date:
2016-06-15
Study First Post Date Type:
ESTIMATED
Results First Submit Date:
2022-10-25
Results First Submit QC Date:
None
Results First Post Date:
2023-02-24
Results First Post Date Type:
ACTUAL
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2025-11-27
Last Update Post Date:
2025-12-04
Last Update Post Date Type:
ESTIMATED